Tocilizumab for the treatment of rheumatoid arthritis

Tocilizumab is a humanized anti-human IL-6 receptor antibody that specifically inhibits the biological activity of IL-6 by competitively inhibiting the binding of IL-6 to the IL-6 receptor. Clinical trials have shown that tocilizumab 8 mg/kg administered by monthly infusion not only improves clinical signs and symptoms of refractory rheumatoid arthritis but also suppresses radiographic progression. In regard to safety, the most common adverse...